3 years ago

Risperidone in combination with other drugs: Experimental research in individuals with autism spectrum disorder.

Alan Poling, Anita Li, Brian MacNeill, Hugo Curiel
Many individuals with autism spectrum disorder simultaneously receive 2 or more drugs intended to improve their behavior, but few studies have evaluated the effects of such polypharmacy. This article summarizes those studies that have systematically examined the effects of risperidone, an antipsychotic drug that is approved by the U.S. Food and Drug Administration to treat "irritability" in children and adolescents with autism spectrum disorder, in combination with another drug with respect to experimental design, assessment techniques, drug co-administered, reported effects, and participant characteristics. The drug combinations that have been evaluated do not parallel those commonly co-administered to individuals with autism spectrum disorder in the United States, and there is no compelling empirical evidence to support the practice of prescribing risperidone in combination with another drug in an attempt to benefit individuals with autism spectrum disorder. (PsycINFO Database Record

Publisher URL: http://doi.org/10.1037/pha0000144

DOI: 10.1037/pha0000144

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.